J Boultwood

Summary

Affiliation: University of Oxford
Country: UK

Publications

  1. ncbi Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome
    Jacqueline Boultwood
    Leukaemia Research Fund Molecular Haematology Unit, Nuffield Department of Clinical Laboratory Science, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    Blood 99:4638-41. 2002
  2. ncbi Clonality in the myelodysplastic syndromes
    J Boultwood
    Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Headington, Oxford, UK
    Int J Hematol 73:411-5. 2001
  3. ncbi Physical mapping of the human ATX1 homologue (HAH1) to the critical region of the 5q- syndrome within 5q32, and immediately adjacent to the SPARC gene
    J Boultwood
    University Department of Cellular Science, John Radcliffe Hospital, Headington, Oxford, UK
    Hum Genet 106:127-9. 2000
  4. ncbi Transcription mapping of the 5q- syndrome critical region: cloning of two novel genes and sequencing, expression, and mapping of a further six novel cDNAs
    J Boultwood
    Leukaemia Research Fund Molecular Haematology Unit, John Radcliffe Hospital, Headington, 0X3 9DU, United Kingdom
    Genomics 66:26-34. 2000
  5. ncbi Novel genes mapping to the critical region of the 5q- syndrome
    J Boultwood
    Leukaemia Research Fund Molecular Haematology Unit, University Department of Cellular Science, John Radcliffe Hospital, Oxford, United Kingdom
    Genomics 45:88-96. 1997
  6. doi High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression
    J Boultwood
    LRF Molecular Haematology Unit, NDCLS, University of Oxford, John Radcliffe Hospital, Oxford, UK
    Leukemia 24:1139-45. 2010
  7. ncbi Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia
    J Boultwood
    Department of Cellular Science, John Radcliffe Hospital, Oxford, United Kingdom
    Am J Hematol 61:5-9. 1999
  8. ncbi Combined immunophenotyping and FISH identifies the involvement of B-cells in 5q- syndrome
    R J Jaju
    Leukaemia Research Fund Molecular Haematology Unit, Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK
    Genes Chromosomes Cancer 29:276-80. 2000
  9. ncbi Molecular cytogenetic delineation of the critical deleted region in the 5q- syndrome
    R J Jaju
    University Department of Cellular Science, John Radcliffe Hospital, Oxford, United Kingdom
    Genes Chromosomes Cancer 22:251-6. 1998
  10. ncbi Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase
    J Boultwood
    Leukaemia Research Fund Molecular Haematology Unit, Department of Cellular Science, John Radcliffe Hospital, Oxford, UK
    Blood 96:358-61. 2000

Collaborators

Detail Information

Publications35

  1. ncbi Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome
    Jacqueline Boultwood
    Leukaemia Research Fund Molecular Haematology Unit, Nuffield Department of Clinical Laboratory Science, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    Blood 99:4638-41. 2002
    ..These data now afford a comprehensive mutational/expression analysis of all candidate genes assigned to the CDR...
  2. ncbi Clonality in the myelodysplastic syndromes
    J Boultwood
    Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Headington, Oxford, UK
    Int J Hematol 73:411-5. 2001
    ..The determination of whether multipotent HSCs are involved in the MDS clone may be important for the use of autologous stem cell transplantation in these patients...
  3. ncbi Physical mapping of the human ATX1 homologue (HAH1) to the critical region of the 5q- syndrome within 5q32, and immediately adjacent to the SPARC gene
    J Boultwood
    University Department of Cellular Science, John Radcliffe Hospital, Headington, Oxford, UK
    Hum Genet 106:127-9. 2000
    ..Genomic localisation, function and expression would suggest that the HAH1 gene represents a candidate gene for the 5q-syndrome...
  4. ncbi Transcription mapping of the 5q- syndrome critical region: cloning of two novel genes and sequencing, expression, and mapping of a further six novel cDNAs
    J Boultwood
    Leukaemia Research Fund Molecular Haematology Unit, John Radcliffe Hospital, Headington, 0X3 9DU, United Kingdom
    Genomics 66:26-34. 2000
    ..Genomic localization and expression patterns would suggest that the 8 novel cDNAs described in this report represent potential candidate genes for the 5q- syndrome...
  5. ncbi Novel genes mapping to the critical region of the 5q- syndrome
    J Boultwood
    Leukaemia Research Fund Molecular Haematology Unit, University Department of Cellular Science, John Radcliffe Hospital, Oxford, United Kingdom
    Genomics 45:88-96. 1997
    ..Genomic localization and expression patterns would suggest that these newly assigned cDNAs represent potential candidate genes for the 5q- syndrome...
  6. doi High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression
    J Boultwood
    LRF Molecular Haematology Unit, NDCLS, University of Oxford, John Radcliffe Hospital, Oxford, UK
    Leukemia 24:1139-45. 2010
    ..Mutation of ASXL1 represents an important new molecular abnormality in CML...
  7. ncbi Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia
    J Boultwood
    Department of Cellular Science, John Radcliffe Hospital, Oxford, United Kingdom
    Am J Hematol 61:5-9. 1999
    ..These data show that a marked reduction in telomere length is associated with disease progression in CML...
  8. ncbi Combined immunophenotyping and FISH identifies the involvement of B-cells in 5q- syndrome
    R J Jaju
    Leukaemia Research Fund Molecular Haematology Unit, Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK
    Genes Chromosomes Cancer 29:276-80. 2000
    ..This result suggests that in some cases, MDS arises in a multipotent cell with a capacity to differentiate into both myeloid and lymphoid cells...
  9. ncbi Molecular cytogenetic delineation of the critical deleted region in the 5q- syndrome
    R J Jaju
    University Department of Cellular Science, John Radcliffe Hospital, Oxford, United Kingdom
    Genes Chromosomes Cancer 22:251-6. 1998
    ..This 5q- syndrome critical region is telomeric to and distinct from the other critical regions on 5q associated with MDS and acute myeloid leukaemia...
  10. ncbi Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase
    J Boultwood
    Leukaemia Research Fund Molecular Haematology Unit, Department of Cellular Science, John Radcliffe Hospital, Oxford, UK
    Blood 96:358-61. 2000
    ..The measurement of diagnostic TRA may prove to be clinically important in the selection of patients at high risk of disease transformation in CML...
  11. ncbi A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia
    R J Jaju
    LRF Molecular Haematology Unit, Nuffield Department of Clinical Laboratory Sciences, University of Oxford, United Kingdom
    Blood 98:1264-7. 2001
    ..The reciprocal transcript, NSD1-NUP98, was also detected by reverse transcriptase--polymerase chain reaction. This is the first report in which the novel gene NSD1 has been implicated in human malignancy. (Blood. 2001;98:1264-1267)..
  12. doi Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells
    A Pellagatti
    LRF Molecular Haematology Unit, NDCLS, John Radcliffe Hospital, Oxford, UK
    Leukemia 24:756-64. 2010
    ..The deregulated pathways identified are likely to be critical to the MDS HSC phenotype and give new insights into the molecular pathogenesis of this disorder, thereby providing new targets for therapeutic intervention...
  13. ncbi hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia
    L J Campbell
    Leukaemia Research Fund Molecular Haematology Unit, Nuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK
    Leukemia 20:671-9. 2006
    ..hTERT levels were increased in CP patients following successful treatment with imatinib, relative to untreated CP patients. We suggest that reduced hTERT expression directly causes the shortened telomeres observed in CML...
  14. ncbi The human POP2 gene: identification, sequencing, and mapping to the critical region of the 5q- syndrome
    C Fidler
    Leukaemia Research Fund Molecular Haematology Unit, University Department of Cellular Science, Oxford, OX3 9DU, United Kingdom
    Genomics 56:134-6. 1999
  15. pmc Ataxia telangiectasia gene mutations in leukaemia and lymphoma
    J Boultwood
    Leukaemia Research Fund Molecular Haematology Unit, Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, UK
    J Clin Pathol 54:512-6. 2001
    ..The putative hereditary predisposition of B-CLL, although intriguing, warrants further investigation...
  16. ncbi High-mobility group A (HMGA) genes: from solid to liquid tumours?
    J Boultwood
    LRF Molecular Haematology Unit, University of Oxford, John Radcliffe Hospital, Oxford, UK
    Leukemia 19:195-6. 2005
  17. pmc Loss of both CSF1R (FMS) alleles in patients with myelodysplasia and a chromosome 5 deletion
    J Boultwood
    Department of Haematology, John Radcliffe Hospital, Headington, Oxford, United Kingdom
    Proc Natl Acad Sci U S A 88:6176-80. 1991
    ..The loss of the hemopoietic growth factor receptor gene CSF1R may be important in the pathogenesis of human myeloid leukemia...
  18. ncbi Mutations in PTPN11 are rare in adult myelodysplastic syndromes and acute myeloid leukemia
    Fiona Watkins
    Am J Hematol 76:417. 2004
  19. ncbi Identification of acquired somatic mutations in the gene encoding chromatin-remodeling factor ATRX in the alpha-thalassemia myelodysplasia syndrome (ATMDS)
    Richard J Gibbons
    MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, OX3 9DS UK
    Nat Genet 34:446-9. 2003
    ..These findings cast new light on this pleiotropic cofactor, which appears to be an essential component rather than a mere facilitator of globin gene expression...
  20. doi Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays
    Li Wang
    LRF Molecular Haematology Unit, Nuffield Department of Clinical, Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK
    Haematologica 93:994-1000. 2008
    ..Single nucleotide polymorphism array analysis has been shown to detect not only gene deletions but also regions of uniparental disomy that can pinpoint particular regions for mutation analysis...
  21. pmc The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts
    Jacqueline Boultwood
    LRF Molecular Haematology Unit, Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, United Kingdom
    PLoS ONE 3:e1970. 2008
    ..These data provide an important link between inherited and acquired forms of sideroblastic anemia and indicate that ABCB7 is a strong candidate gene for RARS...
  22. doi Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma
    Charles H Lawrie
    Nuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK
    Br J Haematol 141:672-5. 2008
    ..05). This is the first description of circulating microRNAs and suggests that microRNAs have potential as non-invasive diagnostic markers for DLBCL and possibly other cancers...
  23. ncbi Gene expression profiling of CD34+ cells in patients with the 5q- syndrome
    Jacqueline Boultwood
    LRF Molecular Haematology Unit, NDCLS, John Radcliffe Hospital, Oxford, UK
    Br J Haematol 139:578-89. 2007
    ..This study suggests that several of the genes mapping to the CDR of the 5q- syndrome play a role in the pathogenesis of this disorder...
  24. pmc Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients
    Andrea Pellagatti
    Leukaemia Research Fund Molecular Haematology Unit, Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom
    Proc Natl Acad Sci U S A 104:11406-11. 2007
    ..SPARC may play a role in the pathogenesis of the 5q- syndrome...
  25. ncbi Gene silencing by DNA methylation in haematological malignancies
    Jacqueline Boultwood
    LRF Molecular Haematology Unit, NDCLS, John Radcliffe Hospital, Oxford, UK
    Br J Haematol 138:3-11. 2007
    ....
  26. ncbi MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma
    Charles H Lawrie
    Nuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    Int J Cancer 121:1156-61. 2007
    ..001), we suggest that microRNAs could be clinically useful molecular markers for DLBCL as well as other cancers...
  27. ncbi Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype
    Andrea Pellagatti
    Leukaemia Research Fund LRF Molecular Haematology Unit, Nuffield Department of Clinical Laboratory Sciences NDCLS, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom
    Blood 108:337-45. 2006
    ..This study provides important and new insights into the pathophysiology of MDS...
  28. ncbi Gene expression profiling in the myelodysplastic syndromes
    Andrea Pellagatti
    Leukaemia Research Fund Molecular Haematology Unit, Nuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK
    Hematology 10:281-7. 2005
    ..It is clear, however, that these findings should be confirmed in larger sets of MDS patients...
  29. ncbi Delineation of the minimal commonly deleted segment and identification of candidate tumor-suppressor genes in del(9q) acute myeloid leukemia
    David A Sweetser
    Department of Pediatrics, Massachusetts General Hospital, 55 Fruit Street Jackson 904, Boston, MA 02114, USA
    Genes Chromosomes Cancer 44:279-91. 2005
    ..The results of our studies are consistent with a model of tumor suppression mediated by haploinsufficiency of critical genes in del(9q) AML...
  30. ncbi Del (9q) AML: clinical and cytological characteristics and prognostic implications
    Andrew Peniket
    Leukaemia Research Fund Molecular Haematology Unit, John Radcliffe Hospital, Oxford, UK
    Br J Haematol 129:210-20. 2005
    ..It is likely that the deletion of single or multiple tumour suppressor genes located in this region may underlie the pathogenesis of del (9q) AML...
  31. ncbi Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology
    Andrea Pellagatti
    Leukaemia Research Fund Molecular Haematology Unit, Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, UK
    Br J Haematol 125:576-83. 2004
    ..The MDS-specific expression changes identified are likely to be biologically important in the pathophysiology of this disorder...
  32. ncbi Low expression of the putative tumour suppressor gene gravin in chronic myeloid leukaemia, myelodysplastic syndromes and acute myeloid leukaemia
    Jacqueline Boultwood
    Leukaemia Research Fund Molecular Haematology Unit, Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, UK
    Br J Haematol 126:508-11. 2004
    ..We have shown that gravin is consistently down-regulated in the CD34(+)/blast cells of myeloid malignancies and may play a role in the molecular pathogenesis of these disorders...
  33. ncbi Gene expression profiling in polycythemia vera using cDNA microarray technology
    Andrea Pellagatti
    Leukaemia Research Fund, Molecular Haematology Unit, Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom
    Cancer Res 63:3940-4. 2003
    ..These PV-specific expression changes are likely to be biologically important in the pathophysiology of this disorder...
  34. pmc Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS
    Li Zhou
    Albert Einstein College of Medicine, Bronx, NY, USA
    Blood 112:3434-43. 2008
    ..These data directly implicate TGF-beta signaling in the pathobiology of ineffective hematopoiesis and identify TBRI as a potential therapeutic target in low-risk MDS...
  35. ncbi NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q)
    Carrie Fidler
    Haematologica 89:865-6. 2004
    ..NRAS and FLT3 mutations are uncommon in MDS patients with a 5q deletion and TP53 mutation is associated with the more advanced MDS subtypes...